BioCentury
ARTICLE | Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

July 12, 2019 8:47 PM UTC

With new clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's intention to develop multiple sclerosis therapy ibudilast for a differentiated patient population following the approval of two other new therapies this year.

MediciNova Inc. (NASDAQ:MNOV; Tokyo:4875) gained $1.32 (15%) to $10.42 on NASDAQ Friday, adding about $56 million in market cap, after revealing its plans...

BCIQ Company Profiles

MediciNova Inc.